T hiazolidinediones (TZDs), which are known to have potent increases of insulin sensitivity, have been developed for the treatment of NIDDM (1). The mechanism of the insulin-sensitizing effect of TZDs is not precisely determined, although several reports showed their stimulatory effect on insulin receptor and insulin receptor substrate (IRS)-l tyrosine phosphorylation, phosphatidylinositol-3-kinase activity, and GLUT4 expression (1-3). Recently, it has been found that TZDs are highaffinity ligands for the peroxisome proliferator-activated receptor-7 (PPAR-7), which belongs to a nuclear receptor superfamily (4). The expression of PPAR-7 has been shown to be induced very early in adipose cell differentiation, which
T hiazolidinediones (TZDs), which are known to have potent increases of insulin sensitivity, have been developed for the treatment of NIDDM (1) . The mechanism of the insulin-sensitizing effect of TZDs is not precisely determined, although several reports showed their stimulatory effect on insulin receptor and insulin receptor substrate (IRS)-l tyrosine phosphorylation, phosphatidylinositol-3-kinase activity, and GLUT4 expression (1) (2) (3) . Recently, it has been found that TZDs are highaffinity ligands for the peroxisome proliferator-activated receptor-7 (PPAR-7), which belongs to a nuclear receptor superfamily (4) . The expression of PPAR-7 has been shown to be induced very early in adipose cell differentiation, which provided potency of adipocyte differentiation cooperatively with CCAAT/enhancer binding protein a (C/EBPa) (5) . After the expression of PPAR-7 and C/EBPa, adipocyte-specific genes are induced to be expressed after the treatment of adipogenic agents, such as insulin, glucocorticoid, and isobutlymethylxanthine (IBMX). The addition of TZDs to preadipocytes is known to induce differentiation into mature adipocytes and enhance expression of the adipocyte-specific genes (6) . Thus, TZDs are indicated to elicit some potential effects on preadipocytes via activation of PPAR-7. By contrast, the effects of these molecules on mature adipocytes have not been fully investigated. It is also necessary to identify their target genes on the mature adipocytes to analyze the in vivo effects of TZDs.
In this study, we tried to search the genes regulated by TZDs in fully differentiated 3T3-L1 adipocytes. For this purpose, we used the mRNA differential display method (7). We obtained one clone whose expression was downregulated by TZDs. This clone corresponded to the partial sequences of stearoyl-CoA desaturase 1 (SCD1) gene (8) . We demonstrate that TZDs decreased SCD1 mRNA levels in 3T3-L1 adipocytes. We also show that TZDs changed fatty acid composition in these cells.
RESEARCH DESIGN AND METHODS

Chemicals.
Troglitazone was from Sankyo Pharmaceuticals (Tokyo, Japan), pioglitazone was from Takeda Pharmaceuticals (Osaka, Japan), and WY-14,643 was from Sigma (St. Louis, MO). All other reagents were of analytical grade. Cell culture. Mouse preadipocyte cell line 3T3-L1 (9) was obtained from American Type Culture Collection (Rockville, MD). The cells were grown in basal medium (Dulbecco's modified Eagle's medium [DMEM]) containing 4.5 g/1 glucose, 50 ug/ml streptomycin sulfate, 50,000 U/l penicillin G), supplemented with 10% fetal bovine serum (FBS). After confluence, the cells were treated with basal medium supplemented with 100 ng/ml insulin, 0.15 mmol/1 IBMX, and 1 umol/1 dexamethasone for 2 days. The medium was replaced with fresh basal medium every 2 days. After the cells were fully differentiated, the indicated drugs were added to the culture medium and incubated for the indicated time. Then cells were harvested to prepare total RNA for differential display, polymerase chain reaction (PCR), and Northern blot analysis, and for estimation of fatty acid composition. mRNA differential display. mRNA differential display was performed using RNA image kit (GenHunter, Nashville, TN), according to the manufacturer's protocol. Briefly, RNA was isolated from mature 3T3-L1 adipocytes treated with 10 umol/1 troglitazone for 8 or 48 h, using the guanidine isothiocyanate extraction method (10) . Subsequently, each RNA was processed to a reverse transcription reaction using the three 3' poly(A) tail-anchored primers and MMLV reverse transcriptase. Each cDNA was used for subsequent PCR amplification. PCR was performed with cDNA, the same 3'-anchored primer, 5' arbitrary primer, dNTPs, [a- from the sequencing gel. The eluted DNA was reamplified by using the same primer pair, which was cloned into the TA cloning vector (Invitrogen, Carlsbad, CA). Northern blot analysis. Of the total RNA prepared from the 3T3-L1 cells, 10 ug was separated on 1% denaturing formaldehyde agarose gel. Northern blot analysis was performed using 32 P-labeled cDNA probes for SCDl mRNA and aP2 mRNA (11), as previously described (12) . cDNA used as a probe for SCDl mRNA is a clone amplified in differential display PCR. Estimation of composition of fatty acid. The 3T3-L1 cells were washed with phosphate-buffered saline and scraped from the dish. The pelleted cells were homogenized in 1 ml chloroform and vortexed vigorously. After centrifugation at ifiOOg for 5 min, the chloroform phase was taken for the determination of fatty acids. High-performance liquid chromatography (HPLC) was performed for determining the composition of total fatty acids, as previously described (13) . Statistics. Values are means ± SD. Statistical analyses were performed according to Student's t test. A P value <0.05 was considered to be statistically significant.
RESULTS
In searching the genes regulated by TZDs in 3T3-L1 adipocytes, we used the mRNA differential display technique. In PCR using H-Tl 1A (AAGCTTTTTTTTTTTA) and H-AP21 (AAGCTTTCTCTGG) primers, a candidate band in sequence gel was found to be repressed by the treatment with 10 umol/1 troglitazone for 8 and 48 h. By searching the homology in GenBank, this band was found to correspond to the partial sequences of exon 6 in the mouse SCDl gene (8) . Thus, we performed Northern blot analyses using the amplified clone as a probe. As shown in Fig. 1A, 10 umol/1 troglitazone decreased the accumulation of 4.9-kb SCDl mRNA in 3T3-L1 adipocytes. Repetitive experiments showed that this downregulation was observed within 12 h after the treatment of troglitazone. The greatest repression occurred at 24 h and continued until 48 h. The repression of SCDl mRNA by troglitazone was also dose-dependent (Fig. IB) . Densitometric scanning analysis revealed that the treatment with 1 umol/1 troglitazone for 48 h repressed SCDl mRNA levels to 40% of the control levels. The maximal repression to -20% of the control was observed at 10 umol/1. By contrast, troglitazone appeared not to alter fatty acid binding protein aP2 mRNA levels. It had no effect on cell viability, as determined by cell number, and cell morphology (data not shown). As demonstrated in Fig. 2 ,10 umol/1 pioglitazone also decreased SCDl mRNA levels in 3T3-L1 adipocytes, whereas 10 umol/1 of the peroxisome proliferator WY-14,643 showed no apparent effect on the mRNA levels.
SCDl enzyme catalyzes the A 9 -c£s desaturation of a spectrum of methylene-interrupted fatty acyl-CoA substrates (14) . Therefore, we determined fatty acid composition of 3T3-L1 Data are means ± SD of triplicate assays. ND, not detectable. *, t, t, and § denote significant difference from control values; P < 0.05, P < 0.01, P < 0.005, and P < 0.001, respectively.
adipocytes treated with or without 10 umol/1 troglitazone for 48 h. Lipid fraction extracted from the whole cells by chloroform was subjected to HPLC to determine the composition of total fatty acids. Total amounts of extracted fatty acids were 2,950 ± 130 ug/dish in the cells treated with troglitazone, not significantly different from those in the untreated cells (2,630 ± 260 pg/dish). Troglitazone significantly increased the composition (weight percentage) of myristic acid (C14:0), palmitic acid (C16:0), and stearic acid (C18:0) ( Table 1) . By contrast, it significantly decreased the composition of myristoleic acid (C14:l, A (Table 1) . Thus, troglitazone decreased the composition of the unsaturated fatty acids while it increased the composition of the saturated fatty acids. Pioglitazone also elicited almost the same effects as troglitazone on the fatty acid composition in 3T3-L1 adipocytes. WY-14,643 at a concentration of 10 umol/1 had no significant effect, except that it slightly increased the composition of palmitic acid (C16:0) ( Table 1) .
DISCUSSION
From mouse 3T3-L1 adipocyte cDNA, we obtained one clone of which expression was downregulated by troglitazone, according to mRNA differential display method. This clone corresponded to the mouse SCD1 gene. Northern blot analysis showed that SCD1 mRNA levels were repressed in 3T3-L1 adipocytes by 10 umol/1 troglitazone. The SCD1 mRNA levels were also repressed by 10 umol/1 pioglitazone. Analysis of fatty acid composition in the whole-cell extract revealed that troglitazone, as well as pioglitazone, significantly increased the composition of saturated fatty acids (myristic, palmitic, stearic) and decreased the composition of A 9 -czs desaturated fatty acids (myristoleic, palmitoleic, oleic, linoleic). SCD1 enzyme catalyzes the A 9 -ds desaturation of a spectrum of methylene-interrupted fatty acyl-CoA substrates, such as myristryl-CoA, palmityl-CoA, and stearyl-CoA (15). Therefore, our results indicate that TZDs inhibit SCD1 enzyme activity in 3T3-L1 adipocytes by repressing the SCD1 mRNA expression. In the present study, TZDs failed to alter the other adipocyte-specific gene aP2 mRNA levels, hi addition, TZDs had no effect on cell viability and cell morphology (data not shown). Thus, the inhibitory effects of TZDs are indicated to be specific for SCD1 gene expression.
The peroxisome proliferator WY-14,643, which has a higher affinity for PPAR-a but less of an affinity for PPAR-7 (4), showed no apparent effect on SCD1 mRNA levels in 3T3-L1 adipocytes at a concentration of 10 umol/1. WY-14,643 had no apparent effect on fatty acid composition in these cells. Because TZDs are high-affinity ligands for PPAR-7 but not for PPAR-a (4), their effect on SCD1 gene expression is indicated to be mediated by PPAR-7. In this regard, it is of interest to note that the functional PPAR response element (PPRE) has been found in the promoter region of the SCD1 gene (16) .
There have been several findings concerning the regulation of SCD1 gene expression. During 3T3-L1 preadipocyte differentiation, SCD1 mRNA levels increase principally at the level of gene transcription in which C/EBPa is involved (17) . hi differentiated 3T3-L1 adipocytes, polyunsaturated fatty acids (PUFAs) repress SCD1 gene expression (18) . PUFAs are found to be ligands for PPAR-a and PPAR-7 (19) , and PPAR-7 but not PPAR-a is preferentially expressed in 3T3-L1 adipocytes (20) . Thus, the inhibitory effects of PUFAs on SCD1 gene expression in these cells might also be mediated by PPAR-7.
The predominant products catalyzed by SCD1 enzyme (palmitoleic acid and oleic acid) are the major constituents of membrane phospholipids and triglyceride stores in adipocytes (14) . Alteration of the ratio of stearic acid to oleic acid composition, which influences cell membrane fluidity, is implicated in insulin action (21, 22) . Recently, it has been shown that increased SCD1 mRNA levels are associated with increased adiposity (23) . Thus, the TZD-induced decrease in the SCD1 mRNA levels may reflect their pharmacological effects on insulin sensitivity and lipid metabolism. In addition, it has been recently observed that troglitazone improves insulin secretion from pancreatic (3-cells (24) . Since saturated fatty acids are found to stimulate insulin release in the perfused rat pancreas (25) , the TZD-induced increase of the saturated fatty acids might be involved in their effects on insulin secretion.
